Discover how different regions approach and manage Market Access & HTA Assessments with Novartis, GSK, BMS, Gilead, Ministry of Health and more

SMi Group's 20th annual European Pharmaceutical Pricing & Reimbursement takes place on 13-14 October, London. Gain insight into current successes and challenges that leading pharmaceutical organisations are facing with market access and P&R policies, including GlaxoSmithKline, Novartis, Ipsen, National Pharmacy Association, Ministry of Health (Germany), Gilead, Quintiles, Mundipharma, Bristol-Myers Squibb and many more.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

20th annual European Pharmaceutical Pricing and Reimbursement

...high-growth of emerging markets expected to nearly double in their pharmaceutical spending, adding $150-165 Bln by 2016- Tribeca Knowledge, 2014

London, UK (PRWEB UK) 26 July 2014

With the high-growth of emerging markets expected to nearly double in their pharmaceutical spending, adding $150-165 Bln by 2016, pharma companies need to plan synchronised product launches across priority markets globally across very different reimbursement and healthcare systems. With smaller, more frequent and often niche product launches kicking-off around the world, your launch process will need to become slicker and more efficient to ensure success.
(Source: Tribeca Knowledge, Top 5 pharma trends in 2014 that will affect your pharma launch planning, 2014)

Join SMi's 20th annual European Pharmaceutical Pricing and Reimbursement to hear exclusive case studies on the latest HTA regulation developments and other challenges associated to different geographical areas - including the Nordic region, Germany, Turkey, France, Japan, Netherlands and more. Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access.

  • Novartis will provide a session on Turkish Health Transformation Reform: what are does HTR include? What are the implications?
  • GlaxoSmithKline will talk about the of use of 'real world' data in generating early estimates of relative effectiveness
  • Gilead compares different region market access strategies varying to class of drugs
  • The Ministry of Health, Germany, evaluates the latest legislation and the changes in P&R and the German landscape.

For those who are interested in attending there is currently a £300 reduced rate through online registrations, using the following code: SMI7D6Z

--END--

For more information and full programme details, please visit:

20th annual European Pharmaceutical Pricing and Reimbursement
13-14 October, 2014
Marriott Regents Park Hotel, London, UK
http://www.pharmaceuticalpricing.co.uk

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.

We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.

More information can be found at http://www.smi-online.co.uk.


Contact

Attachments